Mehta et al., 2000 - Google Patents
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United StatesMehta et al., 2000
- Document ID
- 14258240796558504975
- Author
- Mehta S
- Brancati F
- Sulkowski M
- Strathdee S
- Szklo M
- Thomas D
- Publication year
- Publication venue
- Annals of internal medicine
External Links
Snippet
Background: Hepatitis C virus (HCV) infection may contribute to the development of diabetes mellitus. This relationship has not been investigated at the population level, and its biological mechanism remains unknown. Objective: To examine the prevalence of type 2 …
- 241000711549 Hepacivirus C 0 title abstract description 88
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mehta et al. | Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States | |
Eslam et al. | Meta‐analysis: insulin resistance and sustained virological response in hepatitis C | |
Imazeki et al. | Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus‐infected and hepatitis C virus‐cleared patients | |
Alberti et al. | Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection | |
Veldt et al. | Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis | |
Seeff et al. | 45-year follow-up of hepatitis C virus infection in healthy young adults | |
Kalantar-Zadeh et al. | Hepatitis C virus and death risk in hemodialysis patients | |
Sulkowski et al. | Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus | |
Fabrizi et al. | Post‐transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta‐analysis of clinical studies | |
Dalton et al. | The role of hepatitis E virus testing in drug‐induced liver injury | |
Koretz et al. | Non-A, non-B post-transfusion hepatitis: looking back in the second decade | |
Liu et al. | Pegylated interferon-α-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial | |
Mallet et al. | Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C | |
Stepanova et al. | Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity | |
Giordanino et al. | Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study | |
Huang et al. | Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? | |
Brown et al. | Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs | |
Pojoga et al. | Impaired health-related quality of life in Romanian patients with chronic viral hepatitis before antiviral therapy | |
Huang et al. | Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection | |
Mehta et al. | Association between hepatitis C virus infection and diabetes mellitus | |
Shiffman et al. | Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3 | |
van Kleef et al. | Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study | |
Huang et al. | Pegylated interferon plus ribavirin therapy improves pancreatic β‐cell function in chronic hepatitis C patients | |
Kuchay et al. | Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes | |
Hallager et al. | Mortality in patients with Chronic Hepatitis C and cirrhosis compared to the general population–a Danish cohort study |